You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Overview

  • Product nameAnti-Caveolin 1 antibodySee all Caveolin 1 primary antibodies ...
  • Description
    Goat polyclonal to Caveolin 1
  • SpecificityNo cross-reactivity expected to Caveolin 2 and Caveolin 3.
  • Tested applicationsICC/IF, IHC-FoFr, WB more details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat, Dog, Pig
  • Immunogen

    Synthetic peptide: DELSEKQVYDAH, corresponding to Internal sequence amino acids 33-44 of Human Caveolin 1

  • Positive controlHuman spleen lysate. Lysate from transfected HEK293 cells transiently expressing Caveolin 1.

Properties

Applications

Our Abpromise guarantee covers the use of ab36152 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
ICC/IF ICC/IF: Use at an assay dependent dilution. See Abreviews.
IHC-FoFr IHC-FoFr: 1/100. PubMed: 18716216
WB WB: Use a concentration of 0.3 - 1 µg/ml. Detects a band of approximately 21, 25 kDa (predicted molecular weight: 20 kDa).

Target

  • FunctionMay act as a scaffolding protein within caveolar membranes. Interacts directly with G-protein alpha subunits and can functionally regulate their activity (By similarity). Involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Its binding to DPP4 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Recruits CTNNB1 to caveolar membranes and may regulate CTNNB1-mediated signaling through the Wnt pathway.
  • Tissue specificityExpressed in muscle and lung, less so in liver, brain and kidney.
  • Involvement in diseaseDefects in CAV1 are the cause of congenital generalized lipodystrophy type 3 (CGL3) [MIM:612526]; also called Berardinelli-Seip congenital lipodystrophy type 3 (BSCL3). Congenital generalized lipodystrophies are autosomal recessive disorders characterized by a near absence of adipose tissue, extreme insulin resistance, hypertriglyceridemia, hepatic steatosis and early onset of diabetes.
  • Sequence similaritiesBelongs to the caveolin family.
  • Post-translational
    modifications
    The initiator methionine for isoform Beta is removed during or just after translation. The new N-terminal amino acid is then N-acetylated.
  • Cellular localizationGolgi apparatus membrane. Cell membrane. Membrane > caveola. Membrane raft. Colocalized with DPP4 in membrane rafts. Potential hairpin-like structure in the membrane. Membrane protein of caveolae.
  • Target information above from: UniProt accession Q03135 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links
  • Alternative names
      CAV 1 antibodyCAV 1 antibodyCAV antibody
      CAV1 antibodyCAV1_HUMAN antibodycaveolae protein, 22 kD antibodycaveolin 1 alpha isoform antibodycaveolin 1 beta isoform antibodyCaveolin 1 caveolae protein 22kDa antibodyCaveolin-1 antibodyCaveolin1 antibodycell growth-inhibiting protein 32 antibodyMSTP085 antibodyOTTHUMP00000025031 antibodyVIP 21 antibodyVIP 21 antibodyVIP21 antibody
    see all

Anti-Caveolin 1 antibody images

  • Anti-Caveolin 1 antibody (ab36152) at 0.3 µg/ml + Human Spleen lysate (35µg protein in RIPA buffer).

    Predicted band size : 20 kDa
    Observed band size : 21,25 kDa (why is the actual band size different from the predicted?)
  • All lanes : Anti-Caveolin 1 antibody (ab36152) at 1 µg/ml

    Lane 1 : HEK293 cell lysate overexpressing Caveolin 1
    Lane 2 : MOCK-transfected HEK293 cell lysate


    Predicted band size : 20 kDa
    Observed band size : 23 kDa (why is the actual band size different from the predicted?)

References for Anti-Caveolin 1 antibody (ab36152)

This product has been referenced in:
  • Hunt CL  et al. The Tyro3 receptor kinase Axl enhances macropinocytosis of Zaire ebolavirus. J Virol 85:334-47 (2011). WB ; Human . Read more (PubMed: 21047970) »
  • Schmidtko A  et al. cGMP produced by NO-sensitive guanylyl cyclase essentially contributes to inflammatory and neuropathic pain by using targets different from cGMP-dependent protein kinase I. J Neurosci 28:8568-76 (2008). IHC-FoFr ; Mouse . Read more (PubMed: 18716216) »

See all 2 Publications for this product

Product Wall

Filter by Application

Filter by Species

Filter by Ratings

Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (Human umbilical vein endothelial cells)
Specification Human umbilical vein endothelial cells
Fixative Paraformaldehyde
Permeabilization Yes - Saponine 0,1%
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 22°C
Username

Verified customer

Submitted Apr 16 2010

Application Immunocytochemistry/ Immunofluorescence
Sample Cow Cell (Bovine aortic endothelial cells)
Specification Bovine aortic endothelial cells
Fixative Paraformaldehyde
Permeabilization Yes - Saponin 0,1%
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 22°C
Username

Verified customer

Submitted Apr 08 2010

Application Immunocytochemistry/ Immunofluorescence
Sample Rat Cell (A7r5 (rat smooth muscle cells))
Specification A7r5 (rat smooth muscle cells)
Fixative Paraformaldehyde
Permeabilization Yes - Saponine 0,1%
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 22°C
Username

Verified customer

Submitted Mar 24 2010

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"